March 28, 2006 -- SGX Pharma signed a $515 million cancer partnership with Novartis; Immunicon will extend its three-year-old collaboration with Pfizer; Medarex will develop a fully human anti-SDF-1 antibody with Ono; Crucell will sell its Rhein Biotech division to Dynavax for $12 million; Inspire Pharma said the FDA wants more information on its dry eye treatment; and GlaxoSmithKline released data showing that Advair was helpful in treating COPD, though it missed endpoints. The Centient Biotech 200™ closed down 35 points at 3939.23, a loss of .87%. More details...
